Prosperity Wealth Management Inc. lowered its position in Mesoblast Limited (NASDAQ:MESO - Free Report) by 47.8% in the 1st quarter, according to the company in its most recent filing with the SEC. The fund owned 48,700 shares of the company's stock after selling 44,545 shares during the quarter. Prosperity Wealth Management Inc.'s holdings in Mesoblast were worth $608,000 as of its most recent SEC filing.
Other large investors also recently added to or reduced their stakes in the company. Lindbrook Capital LLC boosted its stake in Mesoblast by 70.9% in the 4th quarter. Lindbrook Capital LLC now owns 2,172 shares of the company's stock worth $43,000 after purchasing an additional 901 shares during the period. Quadrant Capital Group LLC boosted its stake in Mesoblast by 41.1% in the 4th quarter. Quadrant Capital Group LLC now owns 6,496 shares of the company's stock worth $129,000 after purchasing an additional 1,891 shares during the period. Barclays PLC bought a new position in Mesoblast in the 4th quarter worth about $38,000. JPMorgan Chase & Co. bought a new position in Mesoblast in the 4th quarter worth about $50,000. Finally, BNP Paribas Financial Markets boosted its stake in Mesoblast by 86,566.7% in the 4th quarter. BNP Paribas Financial Markets now owns 2,600 shares of the company's stock worth $51,000 after purchasing an additional 2,597 shares during the period. Hedge funds and other institutional investors own 1.43% of the company's stock.
Wall Street Analysts Forecast Growth
Separately, Cantor Fitzgerald upgraded Mesoblast to a "strong-buy" rating in a research note on Monday, March 31st. One research analyst has rated the stock with a sell rating, one has issued a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, Mesoblast has a consensus rating of "Moderate Buy" and an average price target of $18.00.
Read Our Latest Analysis on MESO
Mesoblast Trading Down 0.7%
Shares of MESO traded down $0.08 during trading hours on Thursday, reaching $11.69. 98,363 shares of the company's stock traded hands, compared to its average volume of 273,102. The company has a debt-to-equity ratio of 0.22, a quick ratio of 0.63 and a current ratio of 0.96. The firm's 50 day simple moving average is $11.32 and its 200-day simple moving average is $14.02. Mesoblast Limited has a 12 month low of $5.78 and a 12 month high of $22.00.
Mesoblast Company Profile
(
Free Report)
Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.
Featured Stories
Before you consider Mesoblast, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Mesoblast wasn't on the list.
While Mesoblast currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
